Clinical trial NCT01661920 - References

Community Acquired Pneumonia — Suitability of Antibiotic Treatment for CAP

Citation(s)

•   Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, Schortgen F, Lasocki S, Veber B, Dehoux M, Bernard M, Pasquet B, Régnier B, Brun-Buisson C, Chastre J, Wolff M; PRORATA trial group
  Use of procalcitonin to reduce patients' exposure to antibi
•   Capelastegui A, España PP, Bilbao A, Martinez-Vazquez M, Gorordo I, Oribe M, Urrutia I, Quintana JM
  Pneumonia: criteria for patient instability on hospital discharge. Chest. 2008 Sep;134(3):595-600. doi: 10.1378/chest.07-3039. Epub 2008 May 19.
•   Chalmers JD, Singanayagam A, Hill AT
  C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am J Med. 2008 Mar;121(3):219-25. doi: 10.1016/j.amjmed.2007.10.033.
•   Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, Clementi E, Gonzalez J, Jusserand D, Asfar P, Perrin D, Fieux F, Aubas S; PneumA Trial Group
  Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a r
•   Christ-Crain M, Müller B
  Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J. 2007 Sep;30(3):556-73. Review.
•   Christ-Crain M, Stolz D, Bingisser R, Müller C, Miedinger D, Huber PR, Zimmerli W, Harbarth S, Tamm M, Müller B
  Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2006 Jul 1;174(1)
•   Dunbar LM, Wunderink RG, Habib MP, Smith LG, Tennenberg AM, Khashab MM, Wiesinger BA, Xiang JX, Zadeikis N, Kahn JB
  High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis. 2003 Sep 15;37(6):752-60
•   Durrington HJ, Summers C
  Recent changes in the management of community acquired pneumonia in adults. BMJ. 2008 Jun 21;336(7658):1429-33. doi: 10.1136/bmj.a285. Review.
•   el Moussaoui R, de Borgie CA, van den Broek P, Hustinx WN, Bresser P, van den Berk GE, Poley JW, van den Berg B, Krouwels FH, Bonten MJ, Weenink C, Bossuyt PM, Speelman P, Opmeer BC, Prins JM
  Effectiveness of discontinuing antibiotic treatment after thre
•   File TM Jr, Niederman MS
  Antimicrobial therapy of community-acquired pneumonia. Infect Dis Clin North Am. 2004 Dec;18(4):993-1016, xi. Review.
•   File TM Jr
  Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia. Clin Infect Dis. 2004 Sep 1;39 Suppl 3:S159-64. Review.
•   Guillemot D, Carbon C, Balkau B, Geslin P, Lecoeur H, Vauzelle-Kervroëdan F, Bouvenot G, Eschwége E
  Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA. 1998 Feb 4;279(5)
•   Halm EA, Fine MJ, Kapoor WN, Singer DE, Marrie TJ, Siu AL
  Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia. Arch Intern Med. 2002 Jun 10;162(11):1278-84.
•   Halm EA, Fine MJ, Marrie TJ, Coley CM, Kapoor WN, Obrosky DS, Singer DE
  Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA. 1998 May 13;279(18):1452-7.
•   Kardas P
  Patient compliance with antibiotic treatment for respiratory tract infections. J Antimicrob Chemother. 2002 Jun;49(6):897-903. Review.
•   Li JZ, Winston LG, Moore DH, Bent S
  Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med. 2007 Sep;120(9):783-90.
•   Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, Macfarlane JT, Read RC, Roberts HJ, Levy ML, Wani M, Woodhead MA; Pneumonia Guidelines Committee of the BTS Standards of Care Committee
  BTS guidelines for the management of community acquir
•   Mandell LA, File TM Jr
  Short-course treatment of community-acquired pneumonia. Clin Infect Dis. 2003 Sep 15;37(6):761-3. Epub 2003 Aug 28.
•   Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, Torres A, Whitney CG; Infectious Diseases Society of America; American Thoracic Society
  Infectious Diseases Society of America/America
•   Menéndez R, Cavalcanti M, Reyes S, Mensa J, Martinez R, Marcos MA, Filella X, Niederman M, Torres A
  Markers of treatment failure in hospitalised community acquired pneumonia. Thorax. 2008 May;63(5):447-52. doi: 10.1136/thx.2007.086785. Epub 2008 Feb 1.
•   Montravers P, Fagon JY, Chastre J, Lecso M, Dombret MC, Trouillet JL, Gibert C
  Follow-up protected specimen brushes to assess treatment in nosocomial pneumonia. Am Rev Respir Dis. 1993 Jan;147(1):38-44.
•   Nicolau DP
  Predicting antibacterial response from pharmacodynamic and pharmacokinetic profiles. Infection. 2001 Dec;29 Suppl 2:11-5. Review.
•   Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J
  Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med. 2008 Mar 1;177(5):498-505. Epub 2007 Dec 20.
•   Schrag SJ, Peña C, Fernández J, Sánchez J, Gómez V, Pérez E, Feris JM, Besser RE
  Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial. JAMA. 2001 Jul 4;286(1):49-56.
•   Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, Neidert S, Fricker T, Blum C, Schild U, Regez K, Schoenenberger R, Henzen C, Bregenzer T, Hoess C, Krause M, Bucher HC, Zimmerli W, Mueller B; ProHOSP Study Group
  Effect of procalci
•   Slama TG, Amin A, Brunton SA, File TM Jr, Milkovich G, Rodvold KA, Sahm DF, Varon J, Weiland D Jr; Council for Appropriate and Rational Antibiotic Therapy (CARAT)
  A clinician's guide to the appropriate and accurate use of antibiotics: the Council for App

Suitability of Antibiotic Treatment for Community-acquired Pneumonia

Details for clinical trial NCT01661920